Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir

(RTTNews) - Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in HIV infections with Lenacapavir compared to the background HIV incidence among a geographically diverse population of cisgender men and https://www.nasdaq.com/articles/gilead-sciences-phase-3-data-shows-96-reduction-hiv-infections-lenacapavir